Cellectar Biosciences (CLRB) Other Accumulated Expenses (2018 - 2025)
Cellectar Biosciences (CLRB) posted Other Accumulated Expenses of $499000.0 for Q4 2025, down 61.94% sequentially from $1.3 million in Q4 2024, and down 61.94% YoY from $1.3 million in Q4 2024.
Cellectar Biosciences (CLRB) Other Accumulated Expenses (2018 - 2025) Analysis & Trends
Cellectar Biosciences has reported Other Accumulated Expenses for 8 years, with the latest figure at $499000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 61.94% year-over-year to $499000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $499000.0 (down 61.94% YoY) and the FY2025 annual result came in at $499000.0, down 61.94% from the prior year.
- Other Accumulated Expenses eased to $499000.0 in Q4 2025 per CLRB's latest filing, from $1.3 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.3 million in Q4 2024 and troughed at $1000.0 in Q4 2021.
- A 5-year average of $380800.0 and a median of $85000.0 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2024: Other Accumulated Expenses slumped 99.36% in 2021, then soared 1442.35% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $1000.0 in 2021, then jumped by 700.0% to $8000.0 in 2022, then jumped by 962.5% to $85000.0 in 2023, then jumped by 1442.35% to $1.3 million in 2024, then slumped by 61.94% to $499000.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $499000.0, $1.3 million, and $85000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 499,000.00 |
| Dec 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 85,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2020 | 156,000.00 |
| Dec 31, 2019 | 111,000.00 |
| Dec 31, 2018 | 69,000.00 |